Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP
Posted on: Monday, 19 December 2005, 09:00 CST
PITTSBURGH, Dec. 19 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bisoprolol Fumarate Tablets USP, 5mg and 10mg. Bisoprolol Fumarate Tablets, which are the AB-rated generic version of Duramed Pharmaceuticals' Zebeta(R) Tablets, 5mg & 10 mg, had U.S. sales of approximately $27 million, for the 12-month period ended June 30, 2005, according to IMS Health.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com/.
Mylan Laboratories Inc.
CONTACT: Patrick Fitzgerald, or Kris King of Mylan Laboratories Inc.,+1-724-514-1800
Web site: http://www.mylan.com/
Source: PRNewswire-FirstCall
Related Articles
- Mylan Laboratories: Acquisition Creates a Top-Three Generic Player
- Schaeffer's Upon Further Review Highlights the Following Stocks: Amazon.Com, Google, eBay, Travelzoo, and Mylan Laboratories
- Mylan Laboratories Appoints Carolyn Myers, Ph.D., President of Mylan Technologies Inc.
- Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement
- Mylan Announces Final FDA Approval for Glimepiride Tablets
- Mylan Laboratories Inc. Reports Positive Development From FDA Advisory Committee Vote on EMSAM(R)
- Mylan Laboratories Inc. Announces Executive Appointments
- Drugmaker Mylan Laboratories Reports Decline in Earnings, Revenue
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
 |
 |
User Comments (0)
RSS Feeds